Aspen awaits D-Day as J&J to submit vaccine trial data by 21 January By Antony Sguazzin (Bloomberg) – Johnson & Johnson’s preliminary data from the South African arm of a phase 3 Covid-19 vaccine trial will be ready for submission to US regulators by Jan. 21, according to the head of the country’s Medical Research Council. The timing ties in with the US drug giant’s statement that interim data from the late-stage trial it is conducting in a number of countries is expected by the end of this month. If the data show the one-dose vaccine to be safe and effective, J&J will approach US regulators for an emergency use authorisation in February, and “other health regulatory applications around the world will be made in parallel,” according to the company.